Informazioni generali
  • Categoria della malattia Infezioni e infestazioni , Altro (BASEC)
  • Stato di reclutamento reclutamento non ancora iniziato (BASEC/ICTRP)
  • Luogo dello studio
    Zurigo
    (BASEC)
  • Responsabile dello studio Sascha David sascha.david@usz.ch (BASEC)
  • Fonte dati BASEC: Importato da 01.04.2025 ICTRP: N/A
  • Ultimo aggiornamento 01.04.2025 11:40
HumRes66630 | SNCTP000006346 | BASEC2023-00252

Multicenter Study on the Use of Therapeutic Plasma Exchange as an Additional Treatment for Septic Shock.

  • Categoria della malattia Infezioni e infestazioni , Altro (BASEC)
  • Stato di reclutamento reclutamento non ancora iniziato (BASEC/ICTRP)
  • Luogo dello studio
    Zurigo
    (BASEC)
  • Responsabile dello studio Sascha David sascha.david@usz.ch (BASEC)
  • Fonte dati BASEC: Importato da 01.04.2025 ICTRP: N/A
  • Ultimo aggiornamento 01.04.2025 11:40

Descrizione riassuntiva dello studio

So far, there have been few specific treatment options for your condition, septic shock. Our treatment strategies focus on the following aspects: 1. Anti-infectives (which can include antibiotics), 2. Circulatory stabilization (using fluids or circulatory-active medications, known as catecholamines), and 3. Organ replacement procedures (artificial ventilation, dialysis, etc.). Sepsis is an overreaction of the body to an infection. However, there is still no specific treatment for this dangerous overreaction. We hope that conducting the planned clinical study will provide a protective effect on this aspect of the disease. In addition to standard therapy, a so-called Therapeutic Plasma Exchange (TPE) will take place; this involves exchanging the patient's plasma for healthy donor plasma. The scientific idea behind this method is relatively simple and is based on the attempt to remove harmful factors circulating in the blood, essentially a kind of blood cleansing. The TPE is performed with a corresponding machine, similar to blood washing, and takes about 2 hours. This procedure has been routinely established for other diseases for decades and is regularly performed in large centers (e.g., approximately 500 such treatments are performed annually at USZ, which is more than 1 treatment per day). The spectrum of side effects is low and usually not severe. They mainly consist of allergic reactions and drops in blood pressure, which can be detected early in an intensive care unit and thus treated quickly and effectively. The overarching goal of the study is to demonstrate a survival advantage for patients treated with TPE compared to standard therapy after 28 days.

(BASEC)

Intervento studiato

Therapeutic Plasma Exchange (TPE)

(BASEC)

Malattie studiate

Septic Shock

(BASEC)

Criteri di partecipazione
- Newly occurring septic shock (< 24 hours), (SEPSIS-3 definition) - Norepinephrine (NE) dose ≥ 0.4 μg/kg/min for ≥ 30 min OR NE ≥ 0.3 μg/kg/min + Vasopressin (any dose) - Established vascular access that is indicated for plasma exchange independent of study enrollment (due to an established indication for RRT, an expected need for RRT within the next 48 hours, or for other medical reasons assessed by the treating physician team) (BASEC)

Criteri di esclusione
- Age < 18 or > 80 years - Urogenital infection focus - Pregnant women - Heparin-induced thrombocytopenia - Known (allergic) reaction to frozen fresh plasma (FFP) (BASEC)

Luogo dello studio

Zurigo

(BASEC)

non disponibile

Sponsor

Medizinische Hochschule Hannover Carl-Neuberg-Str. 1 30625 Hannover; Sponsor Representative Switzerland Prof. Dr. med. Sascha David Universitätsspital Zürich Institut für Intensivmedizin Rämistrasse 100 8091 Zürich

(BASEC)

Contatto per ulteriori informazioni sullo studio

Persona di contatto in Svizzera

Sascha David

+41 44 255 8653

sascha.david@usz.ch

Universitätsspital Zürich Institut für Intensivmedizin Rämistrasse 100 8091 Zürich

(BASEC)

Informazioni scientifiche

non disponibile

Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)

Commissione etica Zurigo

(BASEC)

Data di approvazione del comitato etico

01.04.2025

(BASEC)


ID di studio ICTRP
non disponibile

Titolo ufficiale (approvato dal comitato etico)
Randomized, prospective, multicenter, open-label, controlled, parallel group trial investigating the efficacy of add-on plasma-exchange as an adjunctive strategy against septic shock – 2 (EXCHANGE-2) (BASEC)

Titolo accademico
non disponibile

Titolo pubblico
non disponibile

Malattie studiate
non disponibile

Intervento studiato
non disponibile

Tipo di studio
non disponibile

Disegno dello studio
non disponibile

Criteri di inclusione/esclusione
non disponibile

non disponibile

Endpoint primari e secondari
non disponibile

non disponibile

Data di registrazione
non disponibile

Inclusione del primo partecipante
non disponibile

Sponsor secondari
non disponibile

Contatti aggiuntivi
non disponibile

ID secondari
non disponibile

Risultati-Dati individuali dei partecipanti
non disponibile

Ulteriori informazioni sullo studio
non disponibile

Risultati dello studio

Riepilogo dei risultati

non disponibile

Link ai risultati nel registro primario

non disponibile